Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vaccines with interleukin-17 as an adjuvant

A vaccine, IL-17 technology, applied in vaccines, veterinary vaccines, medical preparations containing active ingredients, etc., can solve the problems affecting the immunogenicity and safety of vaccines

Inactive Publication Date: 2017-02-22
BEIJING ADVACCINE BIOTECH
View PDF34 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, not all delivery methods are created equal
Some delivery methods allow for greater compliance within a population of individuals, while others can affect the immunogenicity and / or safety of the vaccine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccines with interleukin-17 as an adjuvant
  • Vaccines with interleukin-17 as an adjuvant
  • Vaccines with interleukin-17 as an adjuvant

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0269] IL-6 and TNF-α

[0270] IL-17A can induce cytokines that are part of the innate immune response, eg, interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α). To determine whether IL-17A can elevate or augment immune responses to viral antigens (eg, "live" or infectious influenza virus antigens) and thus act as an adjuvant, the IL-17A protein was administered prior to administration of infectious viral antigens. Thus, the vaccine comprises rIL-17A and influenza A virus H5N1, wherein the two components of the vaccine are administered at different times. Specifically, the levels of IL-6 and TNF-[alpha] were measured in sera collected from mice receiving IL-17A-containing and non-IL-17A-containing vaccines.

[0271] Two groups of C57BL / 6 mice were treated intraperitoneally (i.p. ) application (or pretreatment). Specifically, rIL-17A is a mouse IL-17A homodimer, and the infectious viral antigen is influenza A virus H5N1. 5LD was administered to two groups of mice on...

Embodiment 2

[0278] IFN-γ and IL-4

[0279] Cytokines, such as interleukin-4 (IL-4) and interferon-gamma (IFN-gamma), control infection caused by influenza A virus. In order to examine whether IL-17A as an adjuvant increases the immune response to antigens via IL-4 and IFN-γ, vaccines containing IL-17A and influenza A viruses H5N1 or H7N9 from administration and administration without IL-17A IL-4 and IFN-γ levels were measured in sera collected from mice vaccinated with influenza A virus H5N1 or H7N9 only.

[0280] Specifically, two groups of C57BL / 6 mice were pretreated intraperitoneally with 0.1 μg and 0.5 μg rIL-17A on day 7 and day 2 before virus infection, respectively. The third group of C57BL / 6 mice did not receive rIL-17A pretreatment. Three groups of mice were treated with 5LD on day 0 50 Influenza A virus H5N1 was challenged. H5N1 virus was administered nasally to mice. A fourth group of C57BL / 6 mice served as controls and were neither pretreated with rIL-17A nor challenged ...

Embodiment 3

[0288] by CD8 + IFN-γ produced by T cells and natural killer cells

[0289] During viral infection, IFN-γ can be produced by CD4 + T cells, CD8 + Secreted by T cells and / or natural killer (NK) cells. To determine the cell population or populations responsible for the increased IFN-γ levels induced by vaccines containing rIL-17A as an adjuvant, IFN-γ positive cells were detected at 6 dpi.

[0290] Specifically, wild-type (ie, C57BL / 6) mice were pretreated intraperitoneally (i.p.) with 0.5 μg of rIL-17A on days 7 and 2 prior to virus administration. A second group of C57BL / 6 mice did not receive rIL-17A pretreatment. These two groups of wild-type mice plus a group of IL-17A knockout mice were treated with 5LD on day 0 50 Influenza A virus H5N1 was challenged. H5N1 virus was administered nasally to mice. Another group of C57BL / 6 mice served as controls and were neither pretreated with rIL-17A nor challenged with influenza A virus H5N1 (ie, untreated mice). Splenocytes wer...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed herein is a vaccine comprising an antigen and IL-17. Also disclosed herein is a method for increasing an immune response in a subject. The method may comprise administering the vaccine to the subject in need thereof.

Description

technical field [0001] The present invention relates to vaccines comprising an antigen and IL-17 and methods of administering said vaccines. Background technique [0002] Vaccines are used to stimulate an immune response in an individual to provide protection against and / or treat a particular disease. Some vaccines contain antigens that induce an immune response. Some antigens elicit strong immune responses, while others elicit weak immune responses. Weak immune responses to antigens can be boosted by including adjuvants in the vaccine. Adjuvants come in many different forms, such as aluminum salts, oil emulsions, sterile compositions of bacteria or other pathogens, cytokines, and the like. [0003] Cytokines are cell-formed proteins that affect the behavior of other cells and, unlike many adjuvants, can modulate specific immune responses. One such cytokine is interleukin-17 (IL-17). IL-17 is a family of cytokines that signal through receptors to induce the production o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/39A61P31/00A61P31/12A61P31/18A61P31/22
CPCA61K39/05A61K39/12A61K2039/525A61K2039/552A61K2039/55527A61K2039/572C12N2750/10034C12N2760/16134C12N2770/10034C12N2770/32134A61K39/39A61P31/00A61P31/12A61P31/18A61P31/22A61K39/464838A61K2239/38A61K39/4611A61K2039/5158A61K39/145A61K2039/52
Inventor 王宾靳津谢晓平何忠淮俞庆龄
Owner BEIJING ADVACCINE BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com